Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 195 entries
View as:

Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01745757 Org: User:
Start: 06/30/12 End: 12/31/22 Due: 12/31/23

Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic

Phase: N/A Priority: Normal
NCT ID: NCT03101046 Org: User:
Start: 11/15/18 End: 12/31/21 Due: 12/31/22

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01443065 Org: User:
Start: 01/31/11 End: 09/30/18 Due: 09/30/19

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00629616 Org: User:
Start: 10/31/07 End: 04/30/18 Due: 04/30/19

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

Phase: N/A Priority: Normal
NCT ID: NCT06625970 Org: User:
Start: 04/10/25 End: 10/31/45 Due: 10/31/46

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06529718 Org: User:
Start: 06/30/25 End: 01/30/29 Due: 01/30/30

Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

Phase: N/A Priority: Normal
NCT ID: NCT03275311 Org: User:
Start: 07/31/14 End: 12/31/26 Due: 12/31/27

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00054587 Org: User:
Start: 06/30/01 End: 12/31/09 Due: 12/31/10

A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes

Phase: N/A Priority: Normal
NCT ID: NCT01620242 Org: User:
Start: 04/30/12 End: 05/27/14 Due: 05/27/15

Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01919879 Org: User:
Start: 10/31/12 End: 12/31/17 Due: 12/31/18

Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Phase: N/A Priority: Normal
NCT ID: NCT02817958 Org: User:
Start: 10/17/16 End: 09/30/28 Due: 09/30/29

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Phase: N/A Priority: Normal
NCT ID: NCT03012581 Org: User:
Start: 06/16/17 End: 11/11/23 Due: 11/11/24

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00003852 Org: User:
Start: 03/31/98 End: 03/31/00 Due: 03/31/01

Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00861094 Org: User:
Start: 03/31/08 End: 12/31/12 Due: 12/31/13

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Phase: N/A Priority: Normal
NCT ID: NCT00287846 Org: User:
Start: 09/30/04 End: 06/30/10 Due: 06/30/11

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature

Phase: N/A Priority: Normal
NCT ID: NCT02505048 Org: User:
Start: 03/31/16 End: 12/31/19 Due: 12/31/20

Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00010244 Org: User:
Start: 09/30/99 End: 03/31/18 Due: 03/31/19

Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003683 Org: User:
Start: 03/31/98 End: 04/30/02 Due: 04/30/03

Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT03132038 Org: User:
Start: 03/24/17 End: 10/20/21 Due: 10/20/22

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05476796 Org: User:
Start: 06/23/23 End: 01/31/27 Due: 01/31/28

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Phase: N/A Priority: Normal
NCT ID: NCT03013335 Org: User:
Start: 01/31/16 End: 06/30/21 Due: 06/30/22

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Phase: N/A Priority: Normal
NCT ID: NCT02997995 Org: User:
Start: 02/15/17 End: 08/28/20 Due: 08/28/21

Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003606 Org: User:
Start: 03/31/96 End: 06/30/01 Due: 06/30/02

Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00066274 Org: User:
Start: 07/23/02 End: 04/01/07 Due: 04/01/08

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00630032 Org: User:
Start: 09/30/07 End: 09/03/20 Due: 09/03/21